From the Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida (Dr Hata); Accelerate Diagnostics, Tucson, Arizona (Dr Humphries); and the Mycotic Diseases Branch, Centers for Disease Control, Atlanta, Georgia (Dr Lockhart).
Arch Pathol Lab Med. 2020 Jan;144(1):107-114. doi: 10.5858/arpa.2018-0508-RA. Epub 2019 Jun 6.
CONTEXT.—: is an emerging yeast species that was first described in 2009. This ascomycetous yeast is notable for resistance to azole antifungal agents, for environmental persistence, and for its ability to contaminate health care environments, resulting in patient colonization and nosocomial infections.
OBJECTIVE.—: To review the state of current knowledge addressing challenges in the accurate identification of in the diagnostic microbiology laboratory, including application of phenotypic, proteomic, and genomic methodologies; characteristics that may predispose the human host to acquiring ; transmission; clinical presentations; treatment modalities; environmental decontamination; and infection prevention in health care settings.
DATA SOURCES.—: The PubMed search engine was used to access peer-reviewed literature published from 2009 to 2019.
CONCLUSIONS.—: The rapid emergence of has presented unique challenges for the areas of laboratory diagnostics and infection prevention and in options for antifungal treatment, which are limited. The current lack of established antifungal susceptibility test breakpoints complicates therapeutic decision making. Enhanced awareness of this pathogen is essential to monitor outbreaks and to reduce the risk of spread within health care environments.
是一种新兴的酵母物种,于 2009 年首次描述。这种子囊菌酵母的特点是对唑类抗真菌药物的耐药性、对环境的持久性以及其污染医疗保健环境的能力,导致患者定植和医院感染。
回顾目前在准确识别诊断微生物实验室中的 的挑战方面的知识状态,包括表型、蛋白质组学和基因组学方法的应用;可能使人类宿主易患 的特征;传播;临床表现;治疗方式;医疗环境中的环境消毒;和感染预防。
使用 PubMed 搜索引擎获取 2009 年至 2019 年发表的同行评议文献。
的迅速出现给实验室诊断和感染预防领域以及有限的抗真菌治疗选择带来了独特的挑战。目前缺乏既定的抗真菌药敏试验折点,这使得治疗决策变得复杂。增强对这种病原体的认识对于监测暴发和减少医疗保健环境中传播的风险至关重要。